TNR Recap: What Patients Say about PsA

Save

Watch this outstanding and informative Tuesday Nite Rheumatology, held on April 5th, 2022 which featured a Patient Perspectives panel discussion, hosted by Dr. Jack Cush.

PsA Panelists included:

- Tena Brown

- Christine Lindsay

- Ashley Krivohlavek

Dactylitis Indicates a Severe PsA Phenotype

Save

A recent study analyzed the impact of dactylitis in disease-modifying antirheumatic drug (DMARD)-naive early psoriatic arthritis (PsA) and found that DMARD-naive PsA patients with dactylitis (dactylitic PsA) have a greater burden of disease than those without dactylitis. 

Apremilast’s Neutral Effects on Cardiovascular Inflammation

Save

An evaluation of a common psoriasis drug's effect on one cardiometabolic risk factor instead showed a favorable impact on a different one.

Increased Cancer Risk with Autoimmune Disorders

Save

The incidence and mortality of cancer among autoimmune diseases (AID) was studied in a large Chinese cohort, demonstrating that while onset time and risks vary, there is an increased risk of malignancy in AID.

Heart Risks Elevated in RA Patients Despite Biologic Tx

Save

Hopes that biologic drugs for rheumatoid arthritis (RA) would cancel the extra cardiovascular risks normally seen with the disease dimmed a little in the face of findings from a population-based study from Scandinavia.

The Effect of Socioeconomic Status on Lupus Outcomes

Save

Socioeconomic status (SES) often associates with poorer outcomes in systemic lupus erythematosus (SLE) patients; and a current study suggests this is unrelated to healthcare access issues.

Tacrolimus Measures Up in Lupus Nephritis Trial

Save

In a phase III trial, oral tacrolimus (Prograf) proved non-inferior to intravenous cyclophosphamide for treating lupus nephritis, researchers said.

FDA Authorizes 2nd Booster for Older and Immunocompromised Individuals

Save

Today, the U.S. Food and Drug Administration authorized a second booster dose of either the Pfizer-BioNTech or the Moderna COVID-19 vaccines for older people and certain immunocompromised individuals.

Differences in Biologic Persistence in Psoriasis and Psoriatic Arthritis

Save

Administrative claims analysis of biologic use in psoriasis (PsO) and psoriatic arthritis (PsA) in French health insurance databases shows that despite widespread biologic use, overall drug persistence (beyond 3 years) was low for PsO and PsA biologics.

Baricitinib Efficacy in Alopecia Areata

Save

The NEJM has published the results of the BRAVE-AA1 and BRAVE-AA2 trials, demonstrating that baricitinib is effective at regrowing hair in alopecia areata (AA) patients, thus paving the way for future regulatory approval for this difficult to treat disorder. 

Comorbidity Drives Risk of Death in Gout Patients

Save

A study of men with gout from the US Veteran’s Health Administration (VHA) shows that excess mortality in gout could be attributed to comorbidities.

SLE Higher Risk of Postoperative Cardiac Events

Save

ACR Open Rheumatology reports that systemic lupus erythematosus (SLE) patients have a higher risk of postoperative major adverse cardiac events (MACE) that can be identified by common cardiac risk measures.

Poor Outcomes in Lupus Patients Not at Target

Save

A prospective, longitudinal systemic lupus erythematosus (SLE) cohort study examined outcomes and showed that failure to control SLE was common and associated with poorer outcomes including organ damage, glucocorticoid exposure, poor quality of life, and increased mortality.

Effect of Intraarticular Steroid Shots on Knee OA Outcomes

Save

In patients with osteoarthritis (OA) of the knee, intra-articular injections of steroids did not increase rates of either disease progression or subsequent knee replacement surgery, researchers said.

Are Shoulder Conditions Incited by Vaccination?

Save

A retrospective cohort study from Kaiser Permanente Southern California intramuscular vaccination given between 2016 and 2017 shows a small but significant increase in shoulder conditions, reported as an adverse event (AE) following intramuscular vaccination in the deltoid muscle. 

Iberdomide in Systemic Lupus Erythematosus

Save

The NEJM reports that systemic lupus erythematosus (SLE) patients treated with iberdomide, a cereblon modulator, was effective at yielding a significant SRI-4 clinical response after 24 weeks. 

Seropositivity Linked to Bronchiectasis in Rheumatoid Arthritis

Save

Rheumatoid arthritis associated bronchiectasis (RA-BR) is uncommon, and is unrelated to interstitial lung disease (ILD), but like ILD, can substantially impact RA outcomes.

Disappointment Behind Acute Gout Hospitalizations

Save

Analysis of emergency department visits from two UK hospitals shows a high rate of hospitalization, and low use of urate-lowering therapies (ULT) and treat-to-target (T2T) management. 

Environmental Pollutants Ups Autoimmune Disease Risk

Save

An Italian environmental study shows that air pollution increases the risk of autoimmune diseases, in particular rheumatoid arthritis, connective tissue diseases (CTDs) and inflammatory bowel diseases (IBD).

Individualized Therapy in Ankylosing Spondylitis

Save

Whether patients with ankylosing spondylitis (AS) would improve substantially with tumor necrosis factor (TNF) inhibitor therapy was predicted with moderate to high accuracy based only on a standard lab test and two measures of disease activity, researchers reported from a modeling study.